Rafferty Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-2,212
| Closed | -$604K | – | 1148 |
|
|
2024
Q2 | $604K | Buy |
2,212
+56
| +3% | +$15.3K | ﹤0.01% | 911 |
|
|
2024
Q1 | $746K | Buy |
2,156
+29
| +1% | +$10K | ﹤0.01% | 880 |
|
|
2023
Q4 | $687K | Sell |
2,127
-52
| -2% | -$16.8K | ﹤0.01% | 896 |
|
|
2023
Q3 | $781K | Buy |
2,179
+91
| +4% | +$32.6K | ﹤0.01% | 852 |
|
|
2023
Q2 | $792K | Buy |
2,088
+165
| +9% | +$62.6K | ﹤0.01% | 872 |
|
|
2023
Q1 | $921K | Buy |
1,923
+79
| +4% | +$37.8K | 0.01% | 817 |
|
|
2022
Q4 | $775K | Buy |
1,844
+701
| +61% | +$295K | 0.01% | 812 |
|
|
2022
Q3 | $477K | Buy |
1,143
+618
| +118% | +$258K | 0.01% | 865 |
|
|
2022
Q2 | $260K | Sell |
525
-136
| -21% | -$67.4K | ﹤0.01% | 965 |
|
|
2022
Q1 | $372K | Sell |
661
-65
| -9% | -$36.6K | ﹤0.01% | 1072 |
|
|
2021
Q4 | $549K | Buy |
726
+41
| +6% | +$31K | ﹤0.01% | 1044 |
|
|
2021
Q3 | $511K | Buy |
685
+239
| +54% | +$178K | ﹤0.01% | 1036 |
|
|
2021
Q2 | $287K | Buy |
446
+22
| +5% | +$14.2K | ﹤0.01% | 1183 |
|
|
2021
Q1 | $242K | Buy |
424
+51
| +14% | +$29.1K | ﹤0.01% | 1120 |
|
|
2020
Q4 | $217K | Sell |
373
-1,329
| -78% | -$773K | ﹤0.01% | 967 |
|
|
2020
Q3 | $877K | Buy |
1,702
+1,220
| +253% | +$629K | 0.01% | 593 |
|
|
2020
Q2 | $218K | Buy |
+482
| New | +$218K | ﹤0.01% | 908 |
|
|
2017
Q3 | – | Sell |
-3,618
| Closed | -$819K | – | 595 |
|
|
2017
Q2 | $819K | Buy |
+3,618
| New | +$819K | 0.02% | 398 |
|